Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q1 FY27 results · Apr–Jun 2026
Suven Life Sciences reported revenue from operations of ₹3.57 crore (up 91.0% from Q1 FY26) and net loss of ₹127.61 crore for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.57 | 1.87 | +91.0% | 1.52 | +134.6% |
| Other income | 7.52 | 0.60 | 13x | 6.78 | +11.0% |
| Total income | 11.09 | 2.47 | +349.6% | 8.30 | +33.6% |
| Profit before tax | (127.61) | (51.52) | Loss widened | (45.60) | Loss widened |
| Net profit for the period | (127.61) | (51.52) | Loss widened | (45.60) | Loss widened |
| EPS, basic (₹) | (4.84) | (2.36) | not comparable | (2.02) | Loss widened |
| Net margin (%) | -3578.7 | -2759.8 | -2999.5 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.57 | 1.87 | +91.0% | 1.52 | +134.6% |
| Other income | 7.52 | 0.59 | 13x | 6.78 | +11.0% |
| Total income | 11.09 | 2.46 | +351.6% | 8.30 | +33.6% |
| Profit before tax | (16.12) | (14.78) | Loss widened | (11.17) | Loss widened |
| Net profit for the period | (16.12) | (14.78) | Loss widened | (11.17) | Loss widened |
| EPS, basic (₹) | (0.61) | (0.68) | not comparable | (0.50) | Loss widened |
| Net margin (%) | -452.0 | -791.7 | -734.6 |
Consolidated
- Filed with BSE
- 06 Aug 2026, 14:27 IST
- Board meeting
- 06 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Aug 2026, 14:27 IST
- Board meeting
- 06 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE